299 related articles for article (PubMed ID: 19842382)
1. Reactogenicity and immunogenicity of a live-attenuated refrigerator-stable varicella vaccine (OKA strain) in healthy seronegative subjects age 10 months to 12 years.
Hadinegoro SR; Hindra IS; Han HH; Gatchalian S; Bock HL
Southeast Asian J Trop Med Public Health; 2009 Sep; 40(5):991-9. PubMed ID: 19842382
[TBL] [Abstract][Full Text] [Related]
2. Reactogenicity and immunogenicity of a varicella vaccine in healthy seronegative and seropositive subjects.
Barzaga NG; Florese RH; Bock HL
Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):259-67. PubMed ID: 12236423
[TBL] [Abstract][Full Text] [Related]
3. Varicella vaccine in non-immune household contacts of children with cancer or leukaemia.
Kappagoda C; Shaw P; Burgess M; Botham S; Cramer L
J Paediatr Child Health; 1999 Aug; 35(4):341-5. PubMed ID: 10457288
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: a randomized controlled study.
Mitra M; Faridi M; Ghosh A; Shah N; Shah R; Chaterjee S; Narang M; Bhattacharya N; Bhat G; Choudhury H; Kadhe G; Mane A; Roy S
Hum Vaccin Immunother; 2015; 11(2):443-9. PubMed ID: 25692656
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.
Leung TF; Li CK; Hung EC; Chan PK; Mo CW; Wong RP; Chik KW
Eur J Haematol; 2004 May; 72(5):353-7. PubMed ID: 15059071
[TBL] [Abstract][Full Text] [Related]
9. Ten year follow-up of healthy children who received one or two injections of varicella vaccine.
Kuter B; Matthews H; Shinefield H; Black S; Dennehy P; Watson B; Reisinger K; Kim LL; Lupinacci L; Hartzel J; Chan I;
Pediatr Infect Dis J; 2004 Feb; 23(2):132-7. PubMed ID: 14872179
[TBL] [Abstract][Full Text] [Related]
10. Chickenpox vaccines: new drugs. A favourable risk-benefit balance in some situations.
Prescrire Int; 2005 Jun; 14(77):85-91. PubMed ID: 15977369
[TBL] [Abstract][Full Text] [Related]
11. Live attenuated varicella vaccine in healthy 12- to 24-month-old children.
Johnson CE; Shurin PA; Fattlar D; Rome LP; Kumar ML
Pediatrics; 1988 Apr; 81(4):512-8. PubMed ID: 2832819
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months.
Ramkissoon A; Coovadia HM; Jugnundan P; Haffejee IE; Meurice F; Vandevoorde D
S Afr Med J; 1995 Dec; 85(12):1295-8. PubMed ID: 8600589
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).
Bernstein HH; Eves K; Campbell K; Black SB; Twiggs JD; Reisinger KS; Conti RM; Flodmark CE; Rombo L; Klopfer S; Schödel F; Hartzel J; Kuter BJ;
Pediatrics; 2007 Jun; 119(6):e1299-305. PubMed ID: 17502347
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
15. Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults.
Kosuwon P; Sutra S; Kosalaraksa P
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):697-701. PubMed ID: 15689090
[TBL] [Abstract][Full Text] [Related]
16. Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group.
Furth SL; Hogg RJ; Tarver J; Moulton LH; Chan C; Fivush BA;
Pediatr Nephrol; 2003 Jan; 18(1):33-8. PubMed ID: 12488988
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation.
Sasadeusz J; Prince HM; Schwarer A; Szer J; Stork A; Bock HL; Povey M; Nicholson O; Innis BL
Transpl Infect Dis; 2014 Dec; 16(6):1024-31. PubMed ID: 25272081
[TBL] [Abstract][Full Text] [Related]
18. Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina.
Fridman D; Monti A; Bonnet MC; Armoni J; Stamboulian D
Hum Vaccin; 2011 Oct; 7(10):1066-71. PubMed ID: 21989288
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children.
Dennehy PH; Reisinger KS; Blatter MM; Veloudis BA
Pediatrics; 1991 Sep; 88(3):604-7. PubMed ID: 1881743
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children.
Ozaki T; Matsui T; Ichikawa T; Asano Y; Yamanishi K; Takahashi M
Biken J; 1984 Sep; 27(2-3):39-42. PubMed ID: 6100056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
